Clinical trials: Benign Prostate Enlargement
BPH With Symptomatic Lower Urinary Tract Symptoms
ProVee Urethral Expander System IDE Study (ProVIDE)
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia…
- Trial name
- ProVIDE (NCT05186740)
- Testing
- ProVee Urethral Expander System, Urethral Access Sheath
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- ProVerum Medical
Bladder Outlet Obstruction
An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia
The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency with or without the inability to hold your urine until you get to the toilet) are invited to participate in this research study.
- Trial name
- Toviaz (NCT00605319)
- Testing
- Toviaz (Fesoterodine)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Prostatic Hyperplasia
SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin
It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the healthy male volunteers under fasting conditions receive, in each period, the test formulation…
- Trial name
- NCT01262989
- Testing
- Test formulation, Reference formulation
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
This study is designed to compare safety and efficacy of monotherapy finasteride to combination therapy (finasteride and tamsulosin) in Asian men with benign prostatic hyperplasia (BPH) who are at least 50 years of age or older.
- Trial name
- NCT01534351
- Testing
- Finasteride, Tamsulosin
- Volunteers
- 1 people
- Sponsor
- Merck Sharp & Dohme LLC
Benign Prostate Hyperplasia, Erectile Dysfunction
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract Symptoms (BPH-LUTS) and improve their quality of…
- Trial name
- NCT01937871
- Testing
- 5 mg Tadalafil, 0.2 mg Tamsulosin
- Where
- 14 sites in China
- Volunteers
- 909 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of…
- Trial name
- NCT00384930
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS
Benign prostatic hyperplasia (BPH) and its related symptoms are a common condition that affects nearly half of men over age 50 and 90% of men over 80.
- Trial name
- NCT01589263
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- VA Office of Research and Development
Benign Prostatic Hyperplasia
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
- Trial name
- NCT00224133
- Testing
- Silodosin
- Where
- 79 sites in United States
- Volunteers
- 661 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers
The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such…
- Trial name
- NCT00848081
- Testing
- Tadalafil
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 318 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia
To evaluate the improvement in symptoms of Benign Prostatic Hyperplasia (BPH) according to the Prostate Symptom Score (IPSS) and Quality- of- Life (QoL) index after add- on therapy of Umooze twice daily administration for 56 days…
- Trial name
- NCT02313233
- Testing
- Umooze
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Golden Biotechnology Corporation
Benign Prostatic Hypertrophy Requiring Surgical Intervention
Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures
To compare efficiency, in terms of tissue morcellation and removal time, of two commercially available FDA-approved morcellators: the VersaCut and the Piranha in subjects undergoing HoLEP procedure for benign prostatic…
- Trial name
- NCT02195622
- Testing
- Lumenis VersaCut Morcellator, Wolf Piranha Morcellator
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Indiana Kidney Stone Institute
Prostatic Hypertrophy, Benign
Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy
The greenlight laser has an absorption maximum which is exactly the same as for hemoglobin. In the presence of hemoglobin, its application causes vaporization of the tissue and this effect depends on the concentration of…
- Trial name
- NCT00461123
- Testing
- Vardenafil (Levitra, BAY38-9456)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Bayer
Benign Prostate Hyperplasia
Pivotal Study to Assess the Safety and Effectiveness of the iTind Device
The study objectives are to demonstrate the efficacy and safety of the Medi-Tate iTIND as compared to control group (catheter only).
- Trial name
- NCT02506465
- Testing
- iTIND
- Where
- 13 sites in United States, Canada
- Volunteers
- 185 people
- Sponsor
- Medi-Tate Ltd.
Benign Prostatic Hyperplasia
To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.
The purpose of this study is to evaluate the safety and performance of the ProstaCare System in relieving symptoms of urinary outflow obstruction secondary to benign prostatic hyperplasia.
- Trial name
- NCT02962674
- Testing
- prostaFix System
- Where
- 3 sites in New Zealand, Singapore
- Volunteers
- 49 people
- Sponsor
- ProstaCare Singapore Pte. Ltd.
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Single-arm, interventional pivotal clinical trial collecting patient data from use of the AQUABEAM System, a personalized image-guided waterjet resection system that utilizes a high-velocity saline stream to resect and remove…
- Trial name
- WATERII (NCT03123250)
- Testing
- Aquablation
- Where
- 16 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia
Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
The purpose of this study is to determine whether PRX302 is safe and effective in the treatment of moderate to severe Benign Prostatic Hyperplasia (BPH).
- Trial name
- TRIUMPH-1 (NCT00889707)
- Testing
- PRX302
- Where
- 9 sites in Canada
- Volunteers
- 92 people
- Sponsor
- Sophiris Bio Corp
Prostatic Hyperplasia
Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement
Study FDC114615 is a two year, multi-centre, randomised, open-label trial to assess the efficacy of Dutasteride plus tamsulosin when compared to the standard practice of watchful waiting, with a defined escalation to tamsulosin…
- Trial name
- CONDUCT (NCT01294592)
- Testing
- Dutasteride plus tamsulosin, tamsulosin
- Where
- 80 sites in France, Germany and 6 more
- Volunteers
- 742 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.
A bio-equivalence of 2 different capsule formulations in fasted subjects
- Trial name
- NCT02417831
- Testing
- tamsulosin capsules, tamsulosin HCl
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
This non-randomized, interventional study will be conducted in a general practice setting to assess the utility of a benign prostatic enlargement (BPE)/benign prostatic obstruction (BPO) screening tool in conjunction with…
- Trial name
- NCT02757963
- Testing
- Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool, International Prostate Symptom Score (IPSS) screening tool
- Where
- 45 sites in France, Germany and 3 more
- Volunteers
- 1,679 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT00284518
- Testing
- botulinum toxin Type A, normal saline
- Where
- 11 sites in Australia, Austria and 9 more
- Volunteers
- 380 people
- Sponsor
- Allergan